Opendata, web and dolomites

Hyalcis

Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hyalcis project word cloud

Explore the words cloud of the Hyalcis project. It provides you a very rough idea of what is the project "Hyalcis" about.

flexible    adhering    efficiency    pleural    registration    treatment    anticancer    intrapleural    prolonged    provider    competitors    aggressive    situ    precisely    business    obtaining    confirmed    combined    biodegradable    toxicity    diagnose    benefits    200m    financial    medical    surfaces    prevention    construction    innovative    animals    medicinal    die    form    malignant    limiting    months    australia    drug    thin    sufficiently    residual    surgery    tumor    concentrations    mesothelioma    years    protection    reaching    asbestos    recovery    polymeric    release    satisfactory    qualified    preparation    designation    difficult    25    cancer    safety    feedback    hydrophilic    linked    capture    epithelial    achievable    resistant    introduces    market    japan    worldwide    industry    america    districts    proposing    extremely    people    full    film    43    recurrence    pleura    local    successfully    treat    north    agency    mesothelial    planning    entitles    tests    2016    cisplatin    hyalcis    plan    plumestars    feasibility    opportunity    industrialization    curative    company    disease    effectiveness    rare    orphan    solution   

Project "Hyalcis" data sheet

The following table provides information about the project.

Coordinator
PLUMESTARS SRL 

Organization address
address: STRADA INZANI 1
city: PARMA PR
postcode: 43124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.plumestars.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLUMESTARS SRL IT (PARMA PR) coordinator 50˙000.00

Map

 Project objective

Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYALCIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYALCIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.

Read More